Abstract:Background Small interfering RNA (siRNA) holds great promise for treating various lung diseases, but the lack of safe and efficient pulmonary siRNA delivery systems has hindered its advance into the clinics. The epidermal growth factor receptor (EGFR) which promotes cell proliferation, and the programmed cell death ligand 1 (PD-L1) which plays a crucial role in suppressing cytotoxic T cells activity, are two important targets for treating non-small cell lung cancer (NSCLC). Here, we explored the potential of PEG 12 -KL4, a synthetic peptide, to deliver siRNA to various NSCLC cells and to lung tissues in mice. Methods PEG 12 -KL4 was used to transfect siRNAs targeted at both EGFR and PD-L1 into NSCLC cells. Immunoblotting was used to evaluate the siRNA silencing effects in HCC827 and NCI-H1975 NSCLC cells. CD8+ T cell-mediated NSCLC cell killing was employed to demonstrate the functional effects of PD-L1 siRNA knock-down. Fluorescent siRNAs were used to visualise siRNA uptake in cells as well as to enable biodistribution studies in BALB/c mice. Results Our results showed that PEG 12 -KL4 was efficient in mediating siRNA knock-down of EGFR and PD-L1 in various NSCLC cells. Importantly, the PEG 12 -KL4 peptide enabled significantly better siRNA delivery than the commercial Lipofectamine 2000 reagent. We hypothesised that PEG 12 -KL4 peptide enabled siRNA to either escape from or bypass endosomal degradation as indicated by confocal fluorescence imaging. Notably, combined knock-down of EGFR and PD-L1 in NCI-H1975 cells resulted in better effector T cell-mediated cancer cell killing than knock-down of PD-L1 alone. Moreover, biodistribution of PEG 12 -KL4/siRNA complexes following intravenous administration revealed poor lung delivery with the fluorescent siRNA accumulating in the liver. In contrast, intratracheal delivery of PEG 12 -KL4/siRNA complexes resulted in the fluorescent siRNA to be detected in the lung with retarded renal excretion. Conclusion In conclusion, we demonstrated that the co-delivery of siRNAs targeting EGFR and PD-L1 using PEG 12 -KL4 is feasible and represents a promising future strategy to treat NSCLC, whereby pulmonary siRNA delivery is favourable to intravenous administration.

Pulmonary Delivery of Immune Checkpoint Inhibitors Using a Responsive Polyethylene Glycol Nanogel for Treating Lung Metastasis

Echogenic PEGylated PEI-Loaded Microbubble As Efficient Gene Delivery System.

Injectable Nanocomposite Hydrogels Improve Intraperitoneal Co-delivery of Chemotherapeutics and Immune Checkpoint Inhibitors for Enhanced Peritoneal Metastasis Therapy

A Virus-Inspired Inhalable Liponanogel Induces Potent Antitumor Immunity and Regression in Metastatic Lung Tumors

A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer

Nanoparticle‐Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis

Enhancing cancer chemo-immunotherapy by biomimetic nanogel with tumor targeting capacity and rapid drug-releasing in tumor microenvironment

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy

Poly(ethyl Ethylene Phosphate): Overcoming the "polyethylene Glycol Dilemma" for Cancer Immunotherapy and Mrna Vaccination.

474P Evaluation of Gelatinase-Responsive Copolymeric Nanoparticles Targeting PD-1 and TGF-β Pathways for Treating Immune-Resistant Tumor

Pre-Induced ICD Membrane-Coated Carrier-Free Nanoparticles for the Personalized Lung Cancer Immunotherapy

Nanomicelle-Microsphere Composite as a Drug Carrier to Improve Lung-Targeting Specificity for Lung Cancer

Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG 12 -KL4 peptide to the lungs as potential strategy against non-small cell lung cancer

Intelligently Targeted Drug Delivery and Enhanced Antitumor Effect by Gelatinase-Responsive Nanoparticles

Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy

Co-Delivery of Doxorubicin and Anti-PD-L1 Peptide in Lipid/PLGA Nanocomplexes for the Chemo-Immunotherapy of Cancer

An immunostimulatory liponanogel reveals immune activation-enhanced drug delivery and therapeutic efficacy in cancer

Tumor-responsive Covalent Organic Polymeric Nanoparticles Enhancing STING Activation for Cancer Immunotherapy

Polymeric nanocarrier via metabolism regulation mediates immunogenic cell death with spatiotemporal orchestration for cancer immunotherapy

Matrix metalloproteinase 2/9-triggered-release micelles for inhaled drug delivery to treat lung cancer: preparation and in vitro/in vivo studies.

Camouflaging Irgd-Egfr Anchored Human Cytotoxic T-lymphocyte Membranes to the Surface of Nanoparticles Combined with Low-Dose Irradiation: New Approach to Enhance Drug-Delivery Targeting in Gastric Cancer